Goldman Sachs Upgrades Teva Pharma (TEVA) to Conviction Buy

Go back to Goldman Sachs Upgrades Teva Pharma (TEVA) to Conviction Buy

Cantor Offers Thoughts On Teva Pharma (TEVA) Weakness

September 27, 2018 7:28 AM EDT

Cantor Fitzgerald analyst, Louise Chen, reiterated her Neutral rating on shares of Teva Pharma (NYSE: TEVA) after receiving multiple investor inquiries into possible reasons for the recent share price weakness. The analyst did confirm with with the company that there is... More